靶向RhoA-ROCK通路逆转SLE中T细胞功能异常
该研究检测了新SLE队列、RA队列及健康对照PBMC中的ROCK活性,并用Y27632、KD025或辛伐他汀处理SLE T细胞或体外分化的Th17细胞,发现SLE和RA患者ROCK活性显著高于健康对照,且各抑制剂均能降低IL-17和IL-21产生。
要点
- SLE和RA患者PBMC中ROCK活性显著高于健康对照。
- Y27632、KD025或辛伐他汀均可抑制Th17细胞的高ROCK活性。
- 上述抑制剂均能减少SLE T细胞或Th17细胞的IL-17和IL-21产生。
核心结论
- SLE和RA患者PBMC中ROCK活性升高。
- 通过非选择性或选择性方式靶向RhoA-ROCK通路可抑制SLE T细胞或Th17细胞产生IL-17和IL-21。
研究设计与样本
- 研究纳入29例SLE患者、31例RA患者和28例健康对照,用ELISA测定PBMC的ROCK活性。
- SLE T细胞或体外分化的Th17细胞分别用Y27632、KD025或辛伐他汀处理,评估ROCK活性及IL-17、IL-21产生。
- 用NanoString技术评估ROCK抑制剂改变的转录谱。
主要发现
- SLE和RA患者ROCK活性水平显著高于健康对照。
- Th17细胞呈现高ROCK活性,可被Y27632、KD025或辛伐他汀抑制。
- Y27632、KD025或辛伐他汀均降低纯化SLE T细胞或Th17细胞的IL-17和IL-21产生。
- 免疫谱分析显示不同ROCK抑制剂具有重叠和不同的效应。
临床怎么用
- SLE和RA患者PBMC中ROCK活性升高,提示RhoA-ROCK通路可作为潜在干预靶点。
- 靶向RhoA-ROCK通路可抑制SLE T细胞或Th17细胞产生IL-17和IL-21。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Deregulated production of interleukin (IL)-17 and IL-21 contributes to the pathogenesis of autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Production of IL-17 and IL-21 can be regulated by ROCK2, one of the two Rho kinases. Increased ROCK activation was previously observed in an SLE cohort. Here, we evaluated ROCK activity in a new SLE cohort, and an RA cohort, and assessed the ability of distinct inhibitors of the ROCK pathway to suppress production of IL-17 and IL-21 by SLE T cells or human Th17 cells. METHODS: ROCK activity in peripheral blood mononuclear cells (PBMCs) from 29 patients with SLE, 31 patients with RA and 28 healthy controls was determined by ELISA. SLE T cells or in vitro-differentiated Th17 cells were treated with Y27632 (a pan-ROCK inhibitor), KD025 (a selective ROCK2 inhibitor) or simvastatin (which inhibits RhoA, a major ROCK activator). ROCK activity and IL-17 and IL-21 production were assessed. The transcriptional profile altered by ROCK inhibitors was evaluated by NanoString technology. RESULTS: ROCK activity levels were significantly higher in patients with SLE and RA than healthy controls. Th17 cells exhibited high ROCK activity that was inhibited by Y27632, KD025 or simvastatin; each also decreased IL-17 and IL-21 production by purified SLE T cells or Th17 cells. Immune profiling revealed both overlapping and distinct effects of the different ROCK inhibitors. CONCLUSIONS: ROCK activity is elevated in PBMCs from patients with SLE and RA. Production of IL-17 and IL-21 by SLE T cells or Th17 cells can furthermore be inhibited by targeting the RhoA-ROCK pathway via both non-selective and selective approaches.
引用
- Rozo C, Chinenov Y, Maharaj RK, et al. Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. Ann Rheum Dis. 2016. PMID: 28283529. doi:10.1136/annrheumdis-2016-209850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。